
Opinion|Videos|January 10, 2024
Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer
Experts in gynecologic oncology discuss the positive results of TV-301, a confirmatory trial for TV-204, raising the possibility of moving tisotumab vedotin earlier in the treatment of patients with cervical cancer, and the potential to combine it with pembrolizumab.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Testing, Timing, and Toxicity: Maximizing Tepotinib’s Durable Benefit in MET Exon 14 Skipping NSCLC
5


